Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 2/2020

01-04-2020 | NSCLC | Review

Regulation of PD-1/PD-L1 Pathway in Cancer by Noncoding RNAs

Authors: Lei Ding, Shengdi Lu, Yanli Li

Published in: Pathology & Oncology Research | Issue 2/2020

Login to get access

Abstract

Immune checkpoint blockade has demonstrated significant anti-tumor immunity in an array of cancer types, yet the underlying regulatory mechanism of it is still obscure, and many problems remain to be solved. As an inhibitory costimulatory signal of T-cells, the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway can paralyze T-cells at the tumor site, enabling the immune escape of tumor cells. Although many antibodies targeting PD-1/PD-L1 have been developed to block their interaction for the treatment of cancer, the reduced response rate and resistance to the therapies call for further comprehension of this pathway in the tumor microenvironment. MicroRNAs (miRNAs) and long noncoding RNAs (lncRNAs) are two main types of noncoding RNAs that play critical parts in the regulation of immune response in tumorigenesis, including the PD-1/PD-L1 pathway. Here we summarize the most recent studies on the control of this pathway by noncoding RNAs in cancer and hopefully will offer new insights into immune checkpoint blockade therapies.
Literature
1.
Teng MW et al (2008) Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol 84(4):988–993PubMedCrossRef
2.
3.
Ishida Y et al (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11(11):3887–3895PubMedPubMedCentralCrossRef
4.
Dong H et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8(8):793–800PubMedCrossRef
5.
Dong H et al (1999) B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5(12):1365–1369PubMedCrossRef
6.
Freeman GJ et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192(7):1027–1034PubMedPubMedCentralCrossRef
7.
Zhang X et al (2004) Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity 20(3):337–347PubMedCrossRef
8.
Lesterhuis WJ, Steer H, Lake RA (2011) PD-L2 is predominantly expressed by Th2 cells. Mol Immunol 49(1–2):1–3PubMedCrossRef
9.
Chen L (2004) Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4(5):336–347PubMedCrossRef
10.
Sheppard KA et al (2004) PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett 574(1–3):37–41PubMedCrossRef
11.
12.
Zamani MR et al (2016) PD-1/PD-L and autoimmunity: a growing relationship. Cell Immunol 310:27–41PubMedCrossRef
13.
Sharpe AH et al (2007) The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 8(3):239–245PubMedCrossRef
14.
Butte MJ et al (2007) Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27(1):111–122PubMedPubMedCentralCrossRef
15.
Schadendorf D et al (2015) Pooled analysis of Long-term survival data from phase II and phase III trials of Ipilimumab in Unresectable or metastatic melanoma. J Clin Oncol 33(17):1889–1894PubMedPubMedCentralCrossRef
16.
17.
Younes RN et al (2011) Chemotherapy beyond first-line in stage IV metastatic non-small cell lung cancer. Rev Assoc Med Bras (1992) 57(6):686–691CrossRef
18.
Reck M et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer. N Engl J Med 375(19):1823–1833PubMedCrossRef
19.
D'Alterio C et al (2016) CXCR4-CXCL12-CXCR7, TLR2-TLR4, and PD-1/PD-L1 in colorectal cancer liver metastases from neoadjuvant-treated patients. Oncoimmunology 5(12):e1254313PubMedPubMedCentralCrossRef
20.
Sasaki S et al (2018) EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions. Gastric Cancer
21.
Saito H et al (2018) Highly activated PD-1/PD-L1 pathway in gastric Cancer with PD-L1 expression. Anticancer Res 38(1):107–112PubMed
22.
Liu S et al (2017) PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways. Oncotarget 8(59):99901–99912PubMedPubMedCentralCrossRef
23.
Shi W et al (2018) Follicular helper T cells promote the effector functions of CD8(+) T cells via the provision of IL-21, which is downregulated due to PD-1/PD-L1-mediated suppression in colorectal cancer. Exp Cell Res 372(1):35–42PubMedCrossRef
24.
Motzer RJ et al (2015) Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 33(13):1430–1437PubMedCrossRef
25.
26.
27.
Ge Y et al (2013) Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice. Cancer Lett 336(2):253–259PubMedCrossRef
28.
Strickland KC et al (2016) Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget 7(12):13587–13598PubMedPubMedCentralCrossRef
29.
Tan D, Sheng L, Yi QH (2018) Correlation of PD-1/PD-L1 polymorphisms and expressions with clinicopathologic features and prognosis of ovarian cancer. Cancer Biomark 21(2):287–297PubMedCrossRef
30.
Powles T et al (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515(7528):558–562PubMedCrossRef
31.
32.
33.
34.
Topalian SL et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10):1020–1030PubMedPubMedCentralCrossRef
35.
Bray F et al (2018) Global Cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin
36.
Barlesi F et al (2014) Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol 25(5):1044–1052PubMedCrossRef
37.
Ettinger DS et al (2012) Non-small cell lung cancer. J Natl Compr Cancer Netw 10(10):1236–1271CrossRef
38.
Shamai S, Merimsky O (2018) Efficacy and safety of Nivolumab in non-small cell lung cancer patients in Tel-Aviv tertiary medical center: facing the reality. Mol Clin Oncol 9(4):419–422PubMedPubMedCentral
39.
Osa A et al (2018) Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight:3(19)
40.
Nizam A, Aragon-Ching JB (2018) Frontline immunotherapy treatment with nivolumab and ipilimumab in metastatic renal cell cancer: a new standard of care. Cancer Biol Ther:1–2
41.
Long GV et al (2018) Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann Oncol
42.
Hida T (2018) Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety. Ther Adv Respir Dis 12:1753466618801167PubMedPubMedCentralCrossRef
43.
Grimm SE et al (2018) Nivolumab for treating metastatic or Unresectable urothelial Cancer: An evidence review Group perspective of a NICE single technology appraisal. Pharmacoeconomics
44.
45.
Agata Y et al (1996) Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8(5):765–772PubMedCrossRef
46.
Zaric B et al (2018) PD-1 and PD-L1 protein expression predict survival in completely resected lung adenocarcinoma. Clin Lung Cancer 19:e957–e963PubMedCrossRef
47.
Karim R et al (2009) Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res 15(20):6341–6347PubMedCrossRef
48.
PD-1 inhibitors raise survival in NSCLC. Cancer Discov, 2014. 4(1):6
49.
Yang ZZ et al (2015) PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival. Blood Cancer J 5:e281PubMedPubMedCentralCrossRef
50.
Prasanth KV, Spector DL (2007) Eukaryotic regulatory RNAs: an answer to the 'genome complexity' conundrum. Genes Dev 21(1):11–42PubMedCrossRef
51.
Enfield KS et al (2012) Mechanistic roles of noncoding RNAs in lung Cancer biology and their clinical implications. Genet Res Int 2012:737416PubMedPubMedCentral
52.
53.
Bentwich I et al (2005) Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 37(7):766–770PubMedCrossRef
54.
Berezikov E et al (2005) Phylogenetic shadowing and computational identification of human microRNA genes. Cell 120(1):21–24PubMedCrossRef
55.
Voorhoeve PM (2010) MicroRNAs: oncogenes, tumor suppressors or master regulators of cancer heterogeneity? Biochim Biophys Acta 1805(1):72–86PubMed
56.
Lee YS, Dutta A (2006) MicroRNAs: small but potent oncogenes or tumor suppressors. Curr Opin Investig Drugs 7(6):560–564PubMed
57.
58.
Ortholan C et al (2009) MicroRNAs and lung cancer: new oncogenes and tumor suppressors, new prognostic factors and potential therapeutic targets. Curr Med Chem 16(9):1047–1061PubMedCrossRef
59.
Wozniak M, Mielczarek A, Czyz M (2016) miRNAs in melanoma: tumor suppressors and oncogenes with prognostic potential. Curr Med Chem 23(28):3136–3153PubMedCrossRef
60.
Bergmann JH, Spector DL (2014) Long non-coding RNAs: modulators of nuclear structure and function. Curr Opin Cell Biol 26:10–18PubMedCrossRef
61.
Cabili MN et al (2011) Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev 25(18):1915–1927PubMedPubMedCentralCrossRef
62.
63.
64.
Pei X, Wang X, Li H (2018) LncRNA SNHG1 regulates the differentiation of Treg cells and affects the immune escape of breast cancer via regulating miR-448/IDO. Int J Biol Macromol 118(Pt A):24–30PubMedCrossRef
65.
Guo Q et al (2015) Comprehensive analysis of lncRNA-mRNA co-expression patterns identifies immune-associated lncRNA biomarkers in ovarian cancer malignant progression. Sci Rep 5:17683PubMedPubMedCentralCrossRef
66.
67.
Ray M, Ruffalo MM, Bar-Joseph Z (2018) Construction of integrated microRNA and mRNA immune cell signatures to predict survival of patients with breast and ovarian cancer. Genes Chromosom Cancer
68.
Miao BP et al (2015) Nasopharyngeal cancer-derived microRNA-21 promotes immune suppressive B cells. Cell Mol Immunol 12(6):750–756CrossRef
69.
Li ZH et al. (2018) MicroRNA-92a promotes tumor growth and suppresses immune function through activation of MAPK/ERK signaling pathway by inhibiting PTEN in mice bearing U14 cervical cancer. Cancer Med
70.
Korsunsky I et al (2017) Two microRNA signatures for malignancy and immune infiltration predict overall survival in advanced epithelial ovarian cancer. J Investig Med 65(7):1068–1076PubMedPubMedCentralCrossRef
71.
Khorrami S et al (2017) MicroRNA-146a induces immune suppression and drug-resistant colorectal cancer cells. Tumour Biol 39(5):1010428317698365PubMedCrossRef
72.
Afonso-Grunz F, Muller S (2015) Principles of miRNA-mRNA interactions: beyond sequence complementarity. Cell Mol Life Sci 72(16):3127–3141PubMedCrossRef
73.
Kataoka K et al (2016) Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature 534(7607):402–406PubMedCrossRef
74.
Du W et al (2017) Variant SNPs at the microRNA complementary site in the B7-H1 3′-untranslated region increase the risk of non-small cell lung cancer. Mol Med Rep 16(3):2682–2690PubMedPubMedCentralCrossRef
75.
Wang W et al (2012) A frequent somatic mutation in CD274 3'-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding. Hum Mutat 33(3):480–484PubMedCrossRef
76.
Gong AY et al (2009) MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes. J Immunol 182(3):1325–1333PubMedCrossRef
77.
Gong AY et al (2010) Cryptosporidium parvum induces B7-H1 expression in cholangiocytes by down-regulating microRNA-513. J Infect Dis 201(1):160–169PubMedCrossRef
78.
Yee D et al (2017) MicroRNA-155 induction via TNF-alpha and IFN-gamma suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells. J Biol Chem 292(50):20683–20693PubMedPubMedCentralCrossRef
79.
Zhang J, Braun MY (2014) PD-1 deletion restores susceptibility to experimental autoimmune encephalomyelitis in miR-155-deficient mice. Int Immunol 26(7):407–415PubMedCrossRef
80.
Cioffi M et al (2017) The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1. Oncotarget 8(13):21609–21625PubMedPubMedCentralCrossRef
81.
Takamizawa J et al (2004) Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64(11):3753–3756PubMedCrossRef
82.
Yu SL et al (2008) MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13(1):48–57PubMedCrossRef
83.
Wang DT et al (2013) miR-150, p53 protein and relevant miRNAs consist of a regulatory network in NSCLC tumorigenesis. Oncol Rep 30(1):492–498PubMedCrossRef
84.
Fu Y et al (2018) Silencing of Long non-coding RNA MIAT sensitizes lung Cancer cells to Gefitinib by epigenetically regulating miR-34a. Front Pharmacol 9:82PubMedPubMedCentralCrossRef
85.
86.
Wang J et al (2014) Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer. Oncogene 33(9):1181–1189PubMedPubMedCentralCrossRef
87.
Shao Y et al (2016) Direct repression of the oncogene CDK4 by the tumor suppressor miR-486-5p in non-small cell lung cancer. Oncotarget 7(23):34011–34021PubMedPubMedCentralCrossRef
88.
Gao ZJ et al (2018) miR-486-5p functions as an oncogene by targeting PTEN in non-small cell lung cancer. Pathol Res Pract 214(5):700–705PubMedCrossRef
89.
Yu S, Geng S, Hu Y (2018) miR-486-5p inhibits cell proliferation and invasion through repressing GAB2 in non-small cell lung cancer. Oncol Lett 16(3):3525–3530PubMedPubMedCentral
90.
91.
Shen Z et al (2015) Effect of miR-18a overexpression on the radiosensitivity of non-small cell lung cancer. Int J Clin Exp Pathol 8(1):643–648PubMedPubMedCentral
92.
93.
Park DH et al (2015) MicroRNA-146a inhibits epithelial mesenchymal transition in non-small cell lung cancer by targeting insulin receptor substrate 2. Int J Oncol 47(4):1545–1553PubMedCrossRef
94.
Kapodistrias N, Bobori C, Theocharopoulou G (2017) MiR-140-3p Downregulation in Association with PDL-1 Overexpression in Many Cancers: A Review from the Literature Using Predictive Bioinformatics Tools. Adv Exp Med Biol 988:225–233PubMedCrossRef
95.
Ji X, Wang E, Tian F (2018) MicroRNA-140 suppresses osteosarcoma tumor growth by enhancing anti-tumor immune response and blocking mTOR signaling. Biochem Biophys Res Commun 495(1):1342–1348PubMedCrossRef
96.
Xie WB et al (2018) MiR-140 expression regulates cell proliferation and targets PD-L1 in NSCLC. Cell Physiol Biochem 46(2):654–663PubMedCrossRef
97.
98.
Jiang D et al (2006) Duplication and expression analysis of multicopy miRNA gene family members in Arabidopsis and rice. Cell Res 16(5):507–518PubMedCrossRef
99.
Senfter D et al (2016) The microRNA-200 family: still much to discover. Biomol Concepts 7(5–6):311–319PubMedCrossRef
100.
Wang R et al (2013) Functional role of miR-34 family in human cancer. Curr Drug Targets 14(10):1185–1191PubMedCrossRef
101.
Vergani E et al (2016) Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. Oncotarget 7(4):4428–4441PubMedCrossRef
102.
103.
Cortez MA et al (2016) PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst:108(1)
104.
105.
Humphries B, Yang C (2015) The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy. Oncotarget 6(9):6472–6498PubMedPubMedCentralCrossRef
106.
Diaz T et al (2014) Role of miR-200 family members in survival of colorectal cancer patients treated with fluoropyrimidines. J Surg Oncol 109(7):676–683PubMedCrossRef
107.
Chen L et al (2014) Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 5:5241PubMedCrossRef
108.
Fujita Y et al (2015) The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer. Mol Ther 23(4):717–727PubMedPubMedCentralCrossRef
109.
Tang D et al (2018) The miR-3127-5p/p-STAT3 axis up-regulates PD-L1 inducing chemoresistance in non-small-cell lung cancer. J Cell Mol Med 22:3847–3856PubMedCentralCrossRefPubMed
110.
Audrito V et al (2017) PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p. Oncotarget 8(9):15894–15911PubMedPubMedCentralCrossRef
111.
Li Q et al (2016) miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion. Oncotarget 7(33):53735–53750PubMedPubMedCentralCrossRef
112.
Rivera LB, Bergers G (2013) Location, location, location: macrophage positioning within tumors determines pro- or antitumor activity. Cancer Cell 24(6):687–689PubMedPubMedCentralCrossRef
113.
Jahangiri A et al (2013) Gene expression profile identifies tyrosine kinase c-met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res 19(7):1773–1783PubMedPubMedCentralCrossRef
114.
Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11(10):889–896PubMedCrossRef
115.
116.
117.
Zhang G et al (2015) microRNA-4717 differentially interacts with its polymorphic target in the PD1 3′ untranslated region: A mechanism for regulating PD-1 expression and function in HBV-associated liver diseases. Oncotarget 6(22):18933–18944PubMedPubMedCentralCrossRef
118.
Zhang Z et al (2008) miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Investig 88(12):1358–1366PubMedCrossRef
119.
Yang SM et al (2013) miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology 306:162–168PubMedCrossRef
120.
121.
P LA et al (2018) Up-Regulation of miR-21, miR-25, miR-93, and miR-106b in Gastric Cancer. Iran Biomed J 22(6):367–373CrossRef
122.
Zhang H et al (2012) miR-21 downregulated TCF21 to inhibit KISS1 in renal cancer. Urology 80(6):1298–1302 e1PubMedCrossRef
123.
An F, Liu Y, Hu Y (2017) miR-21 inhibition of LATS1 promotes proliferation and metastasis of renal cancer cells and tumor stem cell phenotype. Oncol Lett 14(4):4684–4688PubMedPubMedCentralCrossRef
124.
Winther M et al (2015) Evaluation of miR-21 and miR-375 as prognostic biomarkers in esophageal cancer. Acta Oncol 54(9):1582–1591PubMedCrossRef
125.
Wen SW et al (2015) Association of miR-21 with esophageal cancer prognosis: a meta-analysis. Genet Mol Res 14(2):6578–6582PubMedCrossRef
126.
Fu C et al (2014) The expression of miR-21 and miR-375 predict prognosis of esophageal cancer. Biochem Biophys Res Commun 446(4):1197–1203PubMedCrossRef
127.
Zhang J et al (2012) miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer. Br J Cancer 107(2):352–359PubMedPubMedCentralCrossRef
128.
129.
Deng J et al (2014) Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro. Biochem Biophys Res Commun 443(3):789–795PubMedCrossRef
130.
Xue X et al (2016) MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN. Oncotarget 7(51):84508–84519PubMedPubMedCentralCrossRef
131.
Xia H et al (2017) miR-21 modulates the effect of EZH2 on the biological behavior of human lung cancer stem cells in vitro. Oncotarget 8(49):85442–85451PubMedPubMedCentralCrossRef
132.
Su C et al (2018) MiR-21 improves invasion and migration of drug-resistant lung adenocarcinoma cancer cell and transformation of EMT through targeting HBP1. Cancer Med 7(6):2485–2503PubMedPubMedCentralCrossRef
133.
Yang Y, Guo JX, Shao ZQ (2017) miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: An experimental study. Asian Pac J Trop Med 10(1):87–91PubMedCrossRef
134.
135.
Amankwah EK et al (2013) miR-21, miR-221 and miR-222 expression and prostate cancer recurrence among obese and non-obese cases. Asian J Androl 15(2):226–230PubMedPubMedCentralCrossRef
136.
Zadeh MM, Ranji N, Motamed N (2015) Deregulation of miR-21 and miR-155 and their putative targets after silibinin treatment in T47D breast cancer cells. Iran J Basic Med Sci 18(12):1209–1214PubMedPubMedCentral
137.
Fragni M et al (2016) The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines. Naunyn Schmiedeberg's Arch Pharmacol 389(5):529–538CrossRef
138.
Yang CH et al (2015) The oncogenic microRNA-21 inhibits the tumor suppressive activity of FBXO11 to promote tumorigenesis. J Biol Chem 290(10):6037–6046PubMedPubMedCentralCrossRef
139.
Iliopoulos D et al (2011) The negative costimulatory molecule PD-1 modulates the balance between immunity and tolerance via miR-21. Eur J Immunol 41(6):1754–1763PubMedCrossRef
140.
141.
142.
143.
144.
145.
146.
Zhu J et al (2014) MiR-20b, −21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. Hum Immunol 75(4):348–353PubMedCrossRef
147.
Shlush LI, Mitchell A (2015) AML evolution from preleukemia to leukemia and relapse. Best Pract Res Clin Haematol 28(2–3):81–89PubMedCrossRef
148.
Wang X et al (2015) Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signal 27(3):443–452CrossRefPubMed
149.
150.
Xu S et al (2016) miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint. Nat Commun 7:11406PubMedPubMedCentralCrossRef
151.
Tao Z et al (2018) MiR-195/−16 family enhances radiotherapy via T cell activation in the tumor microenvironment by blocking the PD-L1 immune checkpoint. Cell Physiol Biochem 48(2):801–814PubMedCrossRef
152.
Huang F et al (2018) MicroRNA-374b inhibits liver cancer progression via down regulating programmed cell death-1 expression on cytokine-induced killer cells. Oncol Lett 15(4):4797–4804PubMedPubMedCentral
153.
Wu Q et al (2018) miR-375 inhibits IFN-gamma-induced programmed death 1 ligand 1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2/STAT1 signaling. Oncol Rep 39(3):1461–1468PubMed
154.
Wei J et al (2016) MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro-Oncology 18(5):639–648PubMedCrossRef
155.
Jia L et al (2017) miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity. Biochem Biophys Res Commun 488(2):425–431PubMedCrossRef
156.
Zou MX et al (2018) Clinicopathologic implications of CD8(+)/Foxp3(+) ratio and miR-574-3p/PD-L1 axis in spinal chordoma patients. Cancer Immunol Immunother 67(2):209–224PubMedCrossRef
157.
He B, Yan F, Wu C (2018) Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1. Biomed Pharmacother 98:95–101PubMedCrossRef
158.
159.
160.
Haderk F et al (2017) Tumor-derived exosomes modulate PD-L1 expression in monocytes. Science Immunology 2(13)PubMedCrossRef
161.
Zhang C et al (2019) Upregulation of long noncoding RNA SNHG20 promotes cell growth and metastasis in esophageal squamous cell carcinoma via modulating ATM-JAK-PD-L1 pathway. J Cell Biochem
162.
Gilligan KE, Dwyer RM (2017) Engineering Exosomes for Cancer Therapy. Int J Mol Sci:18(6)
163.
Kazandjian D et al (2016) FDA approval summary: Nivolumab for the treatment of metastatic non-small cell lung Cancer with progression on or after platinum-based chemotherapy. Oncologist 21(5):634–642PubMedPubMedCentralCrossRef
164.
Tanaka K et al. (2013) Tumor-suppressive function of protein-tyrosine phosphatase non-receptor type 23 in testicular germ cell tumors is lost upon overexpression of miR142-3p microRNA. J Biol Chem 288(33): p. 23990-9PubMedCrossRefPubMedCentral
Metadata
Title
Regulation of PD-1/PD-L1 Pathway in Cancer by Noncoding RNAs
Authors
Lei Ding
Shengdi Lu
Yanli Li
Publication date
01-04-2020
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-019-00735-9

Other articles of this Issue 2/2020

Pathology & Oncology Research 2/2020 Go to the issue

Original Article

The Role of O6-methylguanine-DNA Methyltransferase Polymorphisms in Prostate Cancer Susceptibility: a Meta-Analysis

Original Article

The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History

Original Article

C-X-C Chemokine Receptor Type 7 (CXCR-7) Expression in Invasive Ductal Carcinoma of Breast in Association with Clinicopathological Features

Original Article

Preliminary Study on Selected Markers of Oxidative Stress, Inflammation and Angiogenesis in Patients with Bladder Cancer

Original Article

Bioinformatics Analysis Makes Revelation to Potential Properties on Regulation and Functions of Human Sox2

Original Article

High Expression of Angiopoietin-like Protein 4 in Advanced Colorectal Cancer and its Association with Regulatory T Cells and M2 Macrophages
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits